К содержанию
РецензированоEN2016

Is Patent “Evergreening” Restricting Access to Medicine/Device Combination Products?

Reed F. Beall · Jason W. Nickerson · Warren A. Kaplan

Научные статьи · 2016

Аннотация

Not all new drug products are truly new. Some are the result of marginal innovation and incremental patenting of existing products, but in such a way that confers no major therapeutic improvement. This phenomenon, pejoratively known as “evergreening”, can allow manufacturers to preserve market exclusivity, but without significantly bettering the standard of care. Other studies speculate that evergreening is especially problematic for medicine/device combination products, because patents on the device component may outlast expired patents on the medicine component, and thereby keep competing, possibly lessexpensive generic products off the market.

Доказательный фрагмент

«Not all new drug products are truly new.»

Образец извлечения

Демо-превью

Not all new drug products are truly new. Полный текст публикации CiteX не хранит — доступ к первоисточнику открывается по DOI согласно лицензии издателя и выбранному плану.

DOI не указан
Цитирований
0
Тип
Журнал
Страна
Узбекистан
Спросить CiteX об этой работе

Смежные источники